IDEXX Laboratories Stock Price, News & Analysis

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, will participate in two key conferences in early March 2023. On March 2 at 10:00 am EST, CFO Brian McKeon and SVP Michael Schreck will engage in a virtual fireside chat at the BofA Securities Animal Health Summit. Following this, on March 6 at 10:25 am EST, CEO Jay Mazelsky will present at the 44th Annual Raymond James Institutional Investors Conference. Both events will offer live audio webcasts accessible via the IDEXX website. An archived edition will also be available.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) has released an empirical study highlighting ways to address capacity constraints in veterinary practices. The study, titled Finding the Time: Empowering Veterinary Teams to Get the Most Out of Every Day, introduces the Practice Productivity Index™, which identifies opportunities for practices to gain up to 2,000 hours per year. Key findings reveal that 82% of practices are struggling to hire staff, and 85% face technology integration issues. The study emphasizes that optimizing workflow, technology, and culture can significantly enhance productivity, ultimately supporting veterinary staff well-being.

IDEXX Laboratories reported a 3% revenue increase in Q4 2022, reaching $829 million, with 7% organic growth. The Companion Animal Group (CAG) saw a 4% reported and 8% organic revenue growth, driven by strong demand for diagnostic services. EPS rose 8% to $2.05. For 2023, IDEXX forecasts revenue between $3,590 million and $3,690 million, indicating 6.5%-9.5% growth. Expected EPS is $9.27 to $9.75, representing an increase of 16%-21%. Key growth factors include an expanded global premium instrument installed base and solid execution strategies.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the release date for its 2022 fourth quarter and full-year financial results, set for February 6, 2023, before market open. A conference call for analysts will occur at 8:30 a.m. ET on the same day. Investors can access a live webcast of the call and review materials via the IDEXX investor relations page. An archived version will be available after 1:00 p.m. ET on that day. IDEXX is a leader in pet healthcare with over 10,000 employees, delivering diagnostic products and services worldwide.

IDEXX Laboratories (NASDAQ: IDXX) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on January 5, 2023, at 1:15 pm ET. Jay Mazelsky, President and CEO, will engage in a fireside chat during the event. The live audio webcast can be accessed through the IDEXX website, with an archived edition available post-event. IDEXX is a leader in pet healthcare innovation, aiming to enhance veterinary medicine and ensure safety in milk and water globally.

IDEXX Laboratories reported third quarter 2022 revenue of $842 million, marking a 4% increase as reported and 8% organically. Growth was supported by a 5% rise in CAG Diagnostics recurring revenue and record premium instrument placements, which rose 10%. Earnings per share (EPS) reached $2.15, reflecting a 6% reported increase. The company adjusted its 2022 revenue guidance to 3.5%-4.5% growth. EPS guidance was updated to $7.74-$7.98, incorporating foreign currency impacts. Strong demand in companion animal healthcare and innovative solutions contributed to these results.

IDEXX Laboratories, a leader in pet healthcare innovation, will release its 2022 third-quarter results on November 1, 2022, before the market opens. An analyst conference call is scheduled for 8:30 a.m. ET on the same day. The call can be accessed via a live webcast on the IDEXX website, with an archived version available after 1:00 p.m. ET for one year. IDEXX is a member of the S&P 500® Index, employs over 10,000 people, and serves customers in over 175 countries.

IDEXX Laboratories reported second quarter revenues of $861 million, reflecting a 4% increase overall and 6.5% organic growth, driven by strong demand in the CAG Diagnostics segment, which grew 4% reported and 7% organically. The company achieved record placements of premium instruments, boosting the global installed base by 15%. Despite these gains, EPS fell 33% to $1.56 due to $80 million in R&D investments. IDEXX revised its full-year revenue guidance to 3% - 5.5% growth, reflecting macroeconomic risks.

IDEXX Laboratories, a leader in pet healthcare innovation, will release its 2022 second quarter financial results on August 2, 2022, before market opening. An analyst conference call is scheduled for 8:30 a.m. ET on the same day.

A live webcast will be accessible via the IDEXX website, with an archived version available post-event for one year. This event illustrates IDEXX's ongoing commitment to transparency and investor engagement, following their track record in diagnostic and software solutions that benefit veterinary practices globally.